Spatial and navigation memory in people with Parkinson's disease and parkinsonism
Compares spatial and navigation memory in people with Parkinson's disease, parkinsonism, and healthy participants.
Plain-language title generated from the registry record
Registry title: VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
Key facts
- Where
- Cassino and Roma, ItalySee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 35 to 80 with Parkinson's disease or atypical parkinsonism (MSA-P or PSP-P), and also healthy volunteers, to study memory for space and for places.
- Age
- 35 to 80 years
- Sex
- All sexes
- Disease stage
- Parkinson's disease or atypical parkinsonism (MSA-P or PSP-P); modified Hoehn and Yahr stage 1 to 3 in the "ON" phase.
Main reasons for not taking part
- Other neurological disorders besides Parkinson's disease and MSA
- Depressive disorders or Beck Depression Inventory-II score above 20
- Musculoskeletal disorders that could impair walking
- Cannot walk 10 meters independently without assistive devices
- MoCA score of 17 or lower, or MMSE score below 24
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 80 years old?
Source: NCT07827963, who can take part
Where in Italy
- IRCCS San Raffaele Cassino - CTC Via G. di Biasio, 1Cassino, ItalyContact: Maria Francesca De Pandis, MD. PhD, NeurologistNo longer taking part
- University of Roma La Sapienza Department of Psychology University of RomeRoma, ItalyContact: Laura PiccardiNo longer taking part
- University of Roma La Sapienza Department of Psychology University of Rome 00185, RomeRoma, ItalyContact: Maria Francesca De Pandis, MD. PhD, NeurologistNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IRCCS San Raffaele Roma
- Trial code
- NCT07827963
- Record updated
- 18 September 2026
- Original description
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism. The protocol is based on the hypothesis that topographical memory may deteriorate before visuospatial memory, suggesting that navigational memory impairment could represent an early indicator of disease progression. The study will include 80 participants stratified into four groups: patients with mild Parkinson's disease, patients with moderate-advanced Parkinson's disease, patients with Parkinsonism, and healthy participants. Visuospatial memory will be assessed using the Corsi Block-tapping Test, while topographical memory will be assessed using the Walking Corsi Test. Walking motor patterns will be recorded using wearable inertial sensors from the MOVIT system, and visual exploration strategies will be assessed using a wearable Pupil Labs eye-tracking system. The integration of cognitive, motor, and eye-tracking measures may support the identification of early neuropsychological markers and the development of tailored neurorehabilitation pathways for individuals with Parkinson's disease and Parkinsonism.Read full original descriptionShow less
VisMemoPD Protocol: An Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism. The protocol is based on the hypothesis that topographical memory may deteriorate before visuospatial memory, suggesting that navigational memory impairment could represent an early indicator of disease progression. The study will include 80 participants stratified into four groups: patients with mild Parkinson's disease, patients with moderate-advanced Parkinson's disease, patients with Parkinsonism, and healthy participants. Visuospatial memory will be assessed using the Corsi Block-tapping Test, while topographical memory will be assessed using the Walking Corsi Test. Walking motor patterns will be recorded using wearable inertial sensors from the MOVIT system, and visual exploration strategies will be assessed using a wearable Pupil Labs eye-tracking system. The integration of cognitive, motor, and eye-tracking measures may support the identification of early neuropsychological markers and the development of tailored neurorehabilitation pathways for individuals with Parkinson's disease and Parkinsonism.
Inclusion: Male and female subjects aged between 35 and 80 years; Diagnosis of Parkinson's disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria; Diagnosis of primary atypical parkinsonism MSA-P, according to the Second Consensus Statement on the Diagnosis of Multiple System Atrophy; Diagnosis of primary atypical parkinsonism PSP-P, according to the Movement Disorder Society criteria for Progressive Supranuclear Palsy; Modified Hoehn and Yahr stage between 1 and 3 during the "ON" phase (Hoehn and Yahr, 1967); Cognitive screening with the Montreal Cognitive Assessment (MoCA) score > 17; Mini-Mental State Examination (MMSE) score ≥ 24 (Folstein et al., 1975); Ability to walk independently for 10 meters without assistive devices; Ability to understand and sign the informed consent form; Ability to comply with study procedures.
Exclusion: Diagnosis of neurological disorders other than Multiple System Atrophy (MSA) and Parkinson's disease; Depressive disorders or Beck Depression Inventory-II (BDI-II) score > 20; Diagnosis of neurological disorders; Depressive disorders or Beck Depression Inventory-II (BDI-II) score > 20; Musculoskeletal disorders that could impair gait performance; Musculoskeletal disorders that could impair gait performance; The study will enroll 20 healthy subjects, matched by age and sex with patients affected by Parkinson's disease (PD) and atypical parkinsonism who will be recruited into the study; The same inclusion criteria will be applied to both groups of patients with Multiple System Atrophy (MSA) and Parkinson's disease; The exclusion criteria will be:.